Effects of Acute Prucalopride Administration in Healthy Volunteers
Primary Purpose
Molecular Mechanisms of Pharmacological Action, Depression, Depressive Disorder
Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Prucalopride
Placebo
Sponsored by
About this trial
This is an interventional basic science trial for Molecular Mechanisms of Pharmacological Action focused on measuring 5-HT4, Prucalopride, Resolor, Emotional Processing, Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
- Male or female
- Aged 18-40 years
- Willing and able to give informed consent for participation in the study
- Sufficiently fluent English to understand and complete the task
Exclusion Criteria:
- Current usage of psychoactive medication (except the contraceptive pill, the Depo-Provera injection or the progesterone implant)
- Any past or current Axis 1 DSM-IV psychiatric disorder
- Significant medical condition
- Current or past gastro-intestinal disorder or irritable bowel syndrome
- Current pregnancy or breastfeeding
- Known lactate deficiency or any other problem absorbing lactose, galactose or glucose
- Current or past history of drug or alcohol dependency
- Participation in a psychological or medical study involving the use of medication within the last 3 months
- Previous participation in a study using the same, or similar, emotional processing tasks
- Smoker > 5 cigarettes per day
- Typically drinks > 6 caffeinated drinks per day
Sites / Locations
- University of Oxford
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Prucalopride
Placebo
Arm Description
1mg prucalopride capsule
Lactose placebo capsule
Outcomes
Primary Outcome Measures
Recognition of positive and negative facial expressions
Accuracy to identify positive vs. negative facial expressions of emotion on the FERT
Secondary Outcome Measures
Recall of emotional words
Number of positive and negative words correctly (and incorrectly) recalled in the EREC task
Recognition of emotional words
Number of positive and negative words correctly (and incorrectly) recognised in the EMEM task
Attentional vigilance to emotional faces
Attentional vigilance to fearful and happy faces in the FDOT task
Recall of words Auditory Verbal Learning Task (AVLT)
Number of items correctly and incorrectly recalled across blocks
Reward and loss sensitivity
Proportion of participants on each trial that chose the correct (high probability) symbol in the win condition, and the incorrect (high probability) symbol in the loss condition of the PILT task
Working memory performance
Mean accuracy and reaction time on 1-back, 2-back and 3-back conditions compared with 0-back condition on the N-back task
Contextual learning
Difference between reaction time and accuracy on novel and repeated arrays in the contextual cueing task
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03863366
Brief Title
Effects of Acute Prucalopride Administration in Healthy Volunteers
Official Title
The Effect of a Single Dose of Prucalopride on Emotional Processing in Healthy Volunteers
Study Type
Interventional
2. Study Status
Record Verification Date
March 2019
Overall Recruitment Status
Completed
Study Start Date
February 7, 2017 (Actual)
Primary Completion Date
August 8, 2017 (Actual)
Study Completion Date
August 8, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Oxford
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study will investigate whether administration of a single dose of the serotonin receptor subtype 4 (5-HT4) partial agonist prucalopride has effects on emotional processing and non-emotional cognition in healthy volunteers, compared to placebo administration. Using an experimental medicine approach, the effects of prucalopride on cognitive biomarkers of antidepressant action will be characterised. In a double-blind design, participants will be randomised to receive a single dose of either prucalopride (1mg) or placebo. All participants will come for a Screening Visit to ensure their suitability for the study. If they meet study criteria, they will be invited to a Research Visit, where they will receive the study medication and wait for two hours while the drug reaches peak levels. After two hours they will be asked to complete a series of computer-based tasks measuring emotional, non-emotional cognitive processing, and reward processing. The primary study hypothesis is that acute prucalopride administration will have positive effects on processing facial expressions of emotion. Secondary hypotheses are that acute prucalopride administration will affect other measures of emotional processing, and non-emotional cognition.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Molecular Mechanisms of Pharmacological Action, Depression, Depressive Disorder, Mood Disorders, Mental Disorder, Antidepressive Agents, Cognition
Keywords
5-HT4, Prucalopride, Resolor, Emotional Processing, Healthy Volunteers
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Participants will be randomly allocated to one of two groups (prucalopride or placebo). Participants in the prucalopride group will receive 1mg of the drug. Participants in the placebo group will receive a lactose placebo. Note that the study is not assessing the safety or efficacy of prucalopride, rather it is using prucalopride to assess the behavioural and neural effects of 5-HT4 partial agonists.
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
41 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Prucalopride
Arm Type
Experimental
Arm Description
1mg prucalopride capsule
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Lactose placebo capsule
Intervention Type
Drug
Intervention Name(s)
Prucalopride
Other Intervention Name(s)
Resolor
Intervention Description
1mg prucalopride tablet, encapsulated in white capsule
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
Lactose placebo tablet, encapsulated in white capsule
Primary Outcome Measure Information:
Title
Recognition of positive and negative facial expressions
Description
Accuracy to identify positive vs. negative facial expressions of emotion on the FERT
Time Frame
Day 1: 2-5 hours post drug administration
Secondary Outcome Measure Information:
Title
Recall of emotional words
Description
Number of positive and negative words correctly (and incorrectly) recalled in the EREC task
Time Frame
Day 1: 2-5 hours post drug administration
Title
Recognition of emotional words
Description
Number of positive and negative words correctly (and incorrectly) recognised in the EMEM task
Time Frame
Day 1: 2-5 hours post drug administration
Title
Attentional vigilance to emotional faces
Description
Attentional vigilance to fearful and happy faces in the FDOT task
Time Frame
Day 1: 2-5 hours post drug administration
Title
Recall of words Auditory Verbal Learning Task (AVLT)
Description
Number of items correctly and incorrectly recalled across blocks
Time Frame
Day 1: 2-5 hours post drug administration
Title
Reward and loss sensitivity
Description
Proportion of participants on each trial that chose the correct (high probability) symbol in the win condition, and the incorrect (high probability) symbol in the loss condition of the PILT task
Time Frame
Day 1: 2-5 hours post drug administration
Title
Working memory performance
Description
Mean accuracy and reaction time on 1-back, 2-back and 3-back conditions compared with 0-back condition on the N-back task
Time Frame
Day 1: 2-5 hours post drug administration
Title
Contextual learning
Description
Difference between reaction time and accuracy on novel and repeated arrays in the contextual cueing task
Time Frame
Day 1: 2-5 hours post drug administration
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Male or female
Aged 18-40 years
Willing and able to give informed consent for participation in the study
Sufficiently fluent English to understand and complete the task
Exclusion Criteria:
Current usage of psychoactive medication (except the contraceptive pill, the Depo-Provera injection or the progesterone implant)
Any past or current Axis 1 DSM-IV psychiatric disorder
Significant medical condition
Current or past gastro-intestinal disorder or irritable bowel syndrome
Current pregnancy or breastfeeding
Known lactate deficiency or any other problem absorbing lactose, galactose or glucose
Current or past history of drug or alcohol dependency
Participation in a psychological or medical study involving the use of medication within the last 3 months
Previous participation in a study using the same, or similar, emotional processing tasks
Smoker > 5 cigarettes per day
Typically drinks > 6 caffeinated drinks per day
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Susannah E Murphy, DPhil
Organizational Affiliation
University of Oxford
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Oxford
City
Oxford
ZIP/Postal Code
OX3 7JX
Country
United Kingdom
12. IPD Sharing Statement
Plan to Share IPD
No
Links:
URL
http://www.perloxford.org
Description
Psychopharmacology and Emotion Research Laboratory
Learn more about this trial
Effects of Acute Prucalopride Administration in Healthy Volunteers
We'll reach out to this number within 24 hrs